Back to search

Article

PARP inhibitors as precision medicine for cancer treatment

2017-03-14

Abstract excerpt

Abstract Personalized or precision medicine is an emerging treatment approach tailored to individuals or certain groups of patients based on their unique characteristics. These types of therapies guided by biomarkers tend to be more effective than traditional approaches, especially in cancer. The inhibitor against poly (ADP-ribose) polymerase (PARP), olaparib (Lynparza, AstraZeneca), which was approved by the US F...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
28d747bc-8456-5025-ac6a-2cf5bed7f353
DOI
10.1093/nsr/nwx027
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
PARP inhibitors as precision medicine for cancer treatmentDOI 10.1093/nsr/nwx027
Select a neighboring publication to make it the new centre.